STAT+: ‘Patchy efforts’ by major insulin makers mean access lags in many poor countries

“The global inequity is so stark and... I think we need to do something about this,” said Jayasree Iyer of the Access to Medicines Foundation.

The three companies that dominate the global market for insulin have launched various programs to expand the reach of their medicines in dozens of low and middle-income countries — but their efforts remain patchy and equitable access consequently remains out of reach, according to a new analysis.

Too often, the manufacturers — Eli Lilly, Sanofi, and Novo Nordisk — do not understand the extent to which the public and private sectors in many poorer countries can afford insulin, the report found. But a more troubling issue is that the companies failed to register their products — both the older human form of insulin and newer analogue varieties — with regulators in many countries.

Continue to STAT+ to read the full story…